Esketamine Market Report 2026

Esketamine Market Overview

• Esketamine market size has reached to $1.51 billion in 2025 • Expected to grow to $2.5 billion in 2030 at a compound annual growth rate (CAGR) of 10.6% • Growth Driver: Increase In Treatment-Resistant Depression Driving The Growth Of The Market Due To Increasing Demand For Alternative Therapies • Market Trend: SPRAVATO Receives FDA Approval As First Monotherapy For Treatment-Resistant Depression, Marking A Breakthrough In TRD Treatment • North America was the largest region in 2025.

What Is Covered Under Esketamine Market?

Esketamine refers to a fast-acting anesthetic and antidepressant derived from ketamine, known for its NMDA receptor antagonist properties. It is used for treatment-resistant depression and major depressive disorder with suicidal ideation, administered as a nasal spray under medical supervision. The main types of esketamine are oral medications, injections, nasal sprays, and others. Oral medications refer to pills or tablets containing esketamine, which are consumed by mouth to treat various conditions like depression. The various indications include major depressive disorder, chronic pain, post-traumatic stress disorder, and anxiety disorders. The patient types involved are adult patients, pediatric patients, and geriatric patients. The various application includes general anesthetic, and treatment-resistant depression and is distributed through several channels such as hospital pharmacy, online pharmacy, and retail pharmacy.

What Is The Esketamine Market Growth Forecast?

The esketamine market size is expected to see rapid growth in the next few years. It will grow to $2.5 billion in 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to increasing prevalence of treatment-resistant depression, demand for fast-acting therapies, expansion of supervised outpatient administration, growing mental health infrastructure, continued clinical research investment. Major trends in the forecast period include growing adoption for treatment-resistant depression, expansion of nasal spray administration, rising use in acute psychiatric care settings, increased monitoring and controlled distribution, growing research into rapid-acting antidepressants.

What Is The Driver Of The Esketamine Market?

The increasing prevalence of treatment-resistant depression (TRD) is expected to propel the growth of the esketamine market in the coming years. Treatment-resistant depression (TRD) refers to depression that doesn't improve after trying at least two different antidepressant medications at proper doses for a sufficient duration. Treatment-resistant depression (TRD) is increasing due to the limited efficacy of conventional antidepressants, leading to prolonged and recurrent depressive episodes. Esketamine helps treatment-resistant depression (TRD) by providing a fast-acting mechanism that targets the NMDA receptors, offering relief for patients who do not respond to traditional antidepressants. For instance, in September 2023, the National Institute of Mental Health (NIMH), a US-based federal agency, reported that, in 2023, about 30% of individuals with major depressive disorder in the U.S. are resistant to standard treatments. Therefore, the rising incidence of treatment-resistant depression is driving the growth of the esketamine industry.

Key Players In The Global Esketamine Market

Major companies operating in the esketamine market are Johnson & Johnson, Janssen Pharmaceuticals, Sage Therapeutics Inc., VistaGen Therapeutics Inc., Cerecor Inc., Celon Pharma S.A., Hikma Pharmaceuticals plc, Seqens Group, Arevipharma GmbH, Nortec Química S.A., Supriya Lifescience Ltd., Maithri Drugs Pvt. Ltd., SynZeal Research Pvt. Ltd., XWPharma Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma Ltd., H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd.

Global Esketamine Market Trends and Insights

Major companies operating in the esketamine market are focusing on developing advanced treatment solutions, such as monotherapy, to enhance depressive symptom relief beyond what placebo offers. Monotherapy refers to the use of a single drug or treatment to manage a disease or medical condition, rather than combining multiple therapies. For instance, in January 2025, Johnson & Johnson, a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). Supported by clinical trials, the approval demonstrated that SPRAVATO could rapidly alleviate depressive symptoms, with significant improvements observed within 24 hours. This breakthrough provides a critical option for approximately 30% of individuals who do not respond to traditional antidepressants, eliminating the need for concurrent oral medications. While SPRAVATO has a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to address potential side effects. This milestone marks a significant advancement in TRD treatment, offering renewed hope for improved patient outcomes.

What Are Latest Mergers And Acquisitions In The Esketamine Market?

In April 2024, Celon Pharma S.A., a Poland-based pharmaceutical company, collaborated with Tang Capital Management LLC to establish Novohale Therapeutics, LLC. This collaboration aims to advance the development of Falkieri, an esketamine dry powder inhalation product, into global Phase 3 clinical trials for bipolar depression. Tang Capital Management LLC is a US-based company that specializes in life sciences and biotechnology.

What Defines the Esketamine Market?

The esketamine market consists of sales of products including spravato, and esketamine injectable formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Esketamine Market Report 2026?

The esketamine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the esketamine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.